Denali Therapeutics (DNLI)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Neurosciencesrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-16. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 31/100 (MEDIUM), 19.6 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 10.72% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Is Denali Therapeutics (DNLI) Reasonably Valued On Future Cash Flow?
- Is Denali Therapeutics (DNLI) Undervalued As Its Share Price Pullback Tests Fair Value?
- Denali Therapeutics (DNLI) Q2 2026 Earnings Call Transcript
- Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026
- Denali Therapeutics Inc. Q2 2026 Earnings Call Summary
- Will Recent Setbacks Impact Growth Prospects of DNLI Stock?
- Can RARE's Approved Product Portfolio Drive Its Next Growth Phase?
- Pompe Disease Market Set for Expansion During the Forecast Period (2026-2036) as Growth is Fueled by Next-Generation ERTs, Newborn Screening, and Pipeline Innovation | DelveInsight
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Denali Therapeutics.
Full DNLI Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.